October 23rd 2024
During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
September 20th 2024
September 19th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More
Phase 1/2 Study Tests Quizartinib/Venetoclax/Decitabine in FLT3-ITD AML
March 11th 2024Musa Yilmaz, MD, discusses the most recent update of the phase 1/2 study of quizartinib, venetoclax, and decitabine in FLT3-internal tandem duplication mutated acute myeloid leukemia and the background behind this research.
Watch
Unraveling Communication Challenges in MDS Treatment
March 4th 2024In an interview with Targeted Oncology, Claire Saxton, MBA, and Ashley Moncrief, discussed the importance of education efforts focused on ensuring that patients with MDS understand their diagnosis and options so that they can make informed decisions about their care.
Read More
Acknowledging Different Considerations for Ruxolitinib in Severe GVHD
February 26th 2024In the second article of a 2-part series, Lori Muffly, MD, MS, leads a discussion on how treatment considerations change when a patient has severe graft-vs-host disease or if the involvement is in the lung and where ruxolitinib fits into treatment.
Read More
Azoles Given Alongside Ruxolitinib Does Not Impact Efficacy in Acute GVHD
February 23rd 2024Findings from an analysis of the REACH2 study, presented at the 2024 Transplantation & Cellular Therapy Meetings, showed that concomitant treatment with azoles does not impact the safety and efficacy of ruxolitinib for patients with acute graft-vs-host-disease.
Read More
Durable Treatment With Ruxolitinib Demonstrated in Real-World cGVHD Population
February 23rd 2024A retrospective study of insurance claims showed patients received ruxolitinib mainly in the second or third line for chronic graft-vs-host disease, with dose adjustment used and no difference shown in time to discontinuation between adult and pediatric patients.
Read More
Ruxolitinib/Belumosudil Combo Leads to 55% Response Rate in GVHD
February 23rd 2024The ruxolitinib and belumosudil combination demonstrated a 55% overall response rate in GVHD, suggesting synergy between inflammatory pathways. The combination was well-tolerated, delayed the need for other therapies.
Read More